ImmunityBio, Inc. (IBRX) News
Follow ImmunityBio, Inc. (IBRX) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 23 public stories across 17 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
M
ImmunityBio Reports Q3 Revenue of $48.7 Million, Up 53%
ImmunityBio reported net product revenue of $48.7 million for the third quarter of 2026, up 53% year over year. U.S. revenue for the first nine months rose 92% to $143.6 million. The company also reported an expanded FDA
EQUITY | Nov 09, 2026, 12:30 PM UTC
M
ImmunityBio and Rafa Win Israeli Approval for ANKTIVA Plus BCG
Israel approved ANKTIVA plus BCG for bladder cancer, according to the headline.
REGULATION | Nov 09, 2026, 12:18 PM UTC
M
ImmunityBio Treats First Patients in Europe With Anktiva Plus BCG
ImmunityBio said the first patients in Europe received Anktiva in combination with Bacillus Calmette-Guérin (BCG).
EQUITY | Nov 04, 2026, 03:23 PM UTC
M
ImmunityBio Shares Rise Nearly 1% as Founder Promotes Sepsis Research
ImmunityBio shares climbed nearly 1% overnight as founder Patrick Soon-Shiong highlighted plans to test its immunotherapy in sepsis. He also renewed a teaser about NantX; the report provides no launch timing or further d
EQUITY | Nov 03, 2026, 04:44 AM UTC
M
ImmunityBio Shares Rise Nearly 1% Overnight After Jim Cramer Endorsement
ImmunityBio shares rose nearly 1% overnight after Jim Cramer called the stock a “very good spec.”
EQUITY | Oct 27, 2026, 07:15 AM UTC
L
ImmunityBio reports Phase 3 ANKTIVA-plus-BCG results
The company reported 84% cystectomy avoidance at three years and complete responses beyond 53 months in BCG-unresponsive NMIBC with CIS, with or without papillary tumors.
EQUITY | Oct 16, 2026, 03:55 PM UTC
M
ImmunityBio Reports Long-Term ANKTIVA Data in Bladder Cancer Study
ImmunityBio said long-term data from its Phase 2/3 QUILT-3.032 study (N=100) were published in the Journal of Urology. The study reported 84% cystectomy avoidance at three years and complete responses beyond 53 months am
EQUITY | Oct 16, 2026, 03:49 PM UTC
M
FDA Expands ImmunityBio’s ANKTIVA Approval to Papillary-Only Bladder Cancer
The expanded indication covers ANKTIVA with BCG for adults with BCG-unresponsive non-muscle-invasive bladder cancer and papillary-only tumors. The FDA decision builds on the drug’s April 2024 approval for patients with c
REGULATION | Oct 15, 2026, 11:01 AM UTC
M
FDA Expands ANKTIVA Approval to Include Papillary-Only NMIBC
ImmunityBio said the FDA expanded ANKTIVA’s indication to include BCG-unresponsive non-muscle invasive bladder cancer patients with papillary-only tumors.
REGULATION | Oct 14, 2026, 09:23 PM UTC
L
FDA Expands ANKTIVA Approval to Cover Papillary and CIS Bladder Cancer
The FDA expanded ANKTIVA’s approval for BCG-unresponsive non-muscle-invasive bladder cancer to cover both papillary and carcinoma in situ (CIS) disease.
REGULATION | Oct 14, 2026, 08:20 PM UTC
M
FDA Approves Broader Anktiva Use for Bladder Cancer
The FDA approved ImmunityBio’s Anktiva for adults with high-grade papillary-only non-muscle invasive bladder cancer that has not responded to BCG therapy.
REGULATION | Oct 14, 2026, 05:06 PM UTC
H
Humana, Evolution Metals & Technologies, Fastly And Other Big Stocks Moving Higher On Friday
U.S. stocks were higher, with the Nasdaq Composite gaining around 100 points on Friday. Shares of Humana Inc (NYSE: HUM ) rose sharply after the company said Friday that its 2027 Medicare Advantage Star Ratings improved
LIVE | Oct 09, 2026, 02:51 PM UTC
H
ImmunityBio Stock Jumps: What's Going On?
ImmunityBio Inc. (NASDAQ: IBRX ) shares are soaring Friday, extending a steadily rising pattern that’s played out over the past several months. ImmunityBio shares are powering higher. What’s behind IBRX gains? ImmunityBi
LIVE | Oct 02, 2026, 05:20 PM UTC
M
ImmunityBio Stock Surges Above $9.44 Resistance
ImmunityBio (IBRX) shares broke above a key resistance level around $9.44, extending a September rally. The stock is on track for its strongest monthly gain since February, surging more than 13% and climbing above $10 fo
EQUITY | Sep 30, 2026, 04:37 PM UTC
L
Biotech Lagged The Broader Market In September — Did Retail Favorites SLS, IBRX, VNDA And IOVA Dodge XBI’s Slump?
Biotech stocks trailed the S&P 500 and Nasdaq-100 in September, yet Iovance Biotherapeutics (IOVA) and ImmunityBio (IBRX) bucked the sector’s decline, while Sellas Life Sciences (SLS) awaited key leukemia data and Vanda
NEWS | Sep 30, 2026, 03:48 AM UTC
L
SLS, IBRX In Focus: Canadian Insurance Giant Manulife’s Unit Raises Stakes Ahead Of Key Cancer Catalysts
Sellas Life Sciences (SLS) and ImmunityBio (IBRX) drew attention on Wednesday after Canadian insurance giant Manulife’s principal operating insurer disclosed that it increased its institutional stakes in both cancer-drug
EQUITY | Sep 10, 2026, 03:04 AM UTC
M
IBRX rises on cancer vaccine trial milestone update
IBRX shares are heading for their best week in over two months after a cancer vaccine trial milestone update tied to Chairman Soon Shiong.
EQUITY | Aug 27, 2026, 05:57 PM UTC
L
SLS, IBRX Eye Fresh Oncology Tailwind As Cathie Wood’s ARK Backs Personalized Cancer-Vaccine Future
SLS, IBRX Eye Fresh Oncology Tailwind As Cathie Wood’s ARK Backs Personalized Cancer-Vaccine Future
EQUITY | Aug 27, 2026, 07:10 AM UTC
L
SLS, IBRX Catch The Eye Of A Major US Pension Fund — And Big Clinical Catalysts Are On The Horizon
SLS, IBRX Catch The Eye Of A Major US Pension Fund — And Big Clinical Catalysts Are On The Horizon
EQUITY | Aug 26, 2026, 08:12 AM UTC
H
IBRX Reports Record Q2 Revenue Up 92%
IBRX Q2 revenue rises 92% year-over-year
EQUITY | Aug 04, 2026, 11:32 AM UTC
H
Immunitybio Receives UAE Marketing Authorization
Immunitybio gets UAE approval for ANKTIVA
EQUITY | Jul 30, 2026, 12:57 AM UTC
H
UAE Approves ImmunityBio's ANKTIVA
UAE grants marketing authorization for ANKTIVA
EQUITY | Jul 29, 2026, 10:50 PM UTC
L
ImmunityBio Insider Sold Shares Worth $1,439,066, According to a Recent SEC Filing
() -- Christobel Selecky, Director, on July 01, 2026, sold 159,478 shares in ImmunityBio (IBRX) for $1,439,066. SEC Filing: Copyright © 2026. All rights reserved. does not provide investment advice. Unauthorized reproduc
REGULATION | Jul 07, 2026, 07:49 AM UTC